Your browser doesn't support javascript.
Pre-existing humoral immunity and CD4+ T cell response correlate with cross-reactivity against SARS-CoV-2 Omicron subvariants after heterologous prime-boost vaccination.
Shen, Ching-Fen; Fu, Yi-Chen; Ho, Tzong-Shiann; Chen, Po-Lin; Lee, Nan-Yao; Tsai, Bo-Yang; Tsai, Pei-Jane; Ko, Wen-Chien; Liu, Ching-Chuan; Cheng, Chao-Min; Shieh, Chi-Chang.
  • Shen CF; Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan, ROC; Department of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan, ROC.
  • Fu YC; Institute of Biomedical Engineering, National Tsing Hua University, Hsinchu 30013, Taiwan, ROC.
  • Ho TS; Department of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan, ROC; Center of Infectious Disease and Signaling Research, National Cheng Kung University, Tainan 70101, Taiwan, ROC; Department of Pediatrics, Tainan Hospital
  • Chen PL; Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan, ROC.
  • Lee NY; Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan, ROC.
  • Tsai BY; Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan, ROC.
  • Tsai PJ; Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan, ROC; Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan, ROC.
  • Ko WC; Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan, ROC.
  • Liu CC; Department of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan, ROC; Center of Infectious Disease and Signaling Research, National Cheng Kung University, Tainan 70101, Taiwan, ROC.
  • Cheng CM; Institute of Biomedical Engineering, National Tsing Hua University, Hsinchu 30013, Taiwan, ROC. Electronic address: chaomin@mx.nthu.edu.tw.
  • Shieh CC; Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan, ROC; Department of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan, ROC. Electronic address: cshieh@mail.ncku.edu.
Clin Immunol ; 251: 109342, 2023 06.
Article in English | MEDLINE | ID: covidwho-2303610
ABSTRACT

BACKGROUND:

Information regarding the heterologous prime-boost COVID vaccination has been fully elucidated. The study aimed to evaluate both humoral, cellular immunity and cross-reactivity against variants after heterologous vaccination.

METHODS:

We recruited healthcare workers previously primed with Oxford/AstraZeneca ChAdOx1-S vaccines and boosted with Moderna mRNA-1273 vaccine boost to evaluate the immunological response. Assay used anti-spike RBD antibody, surrogate virus neutralizing antibody and interferon-γ release assay.

RESULTS:

All participants exhibited higher humoral and cellular immune response after the booster regardless of prior antibody level, but those with higher antibody level demonstrated stronger booster response, especially against omicron BA.1 and BA.2 variants. The pre-booster IFN-γ release by CD4+ T cells correlates with post-booster neutralizing antibody against BA.1 and BA.2 variant after adjustment with age and gender.

CONCLUSIONS:

A heterologous mRNA boost is highly immunogenic. The pre-existing neutralizing antibody level and CD4+ T cells response correlates with post-booster neutralization reactivity against the Omicron variant.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunity, Humoral / COVID-19 Type of study: Experimental Studies / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Clin Immunol Journal subject: Allergy and Immunology Year: 2023 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunity, Humoral / COVID-19 Type of study: Experimental Studies / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Clin Immunol Journal subject: Allergy and Immunology Year: 2023 Document Type: Article